The most widely used and accepted prostate cancer biomarker currently available commercially is the prostate‐specific antigen (PSA) test, which is recognised to be the predictor of choice for prostate cancer diagnosis and screening for many years [140]. This evidence concerns the gene PROS1 and prostate carcinoma.